Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation

Published:2017 Issue:18 Volume:56 Page:2481-2485
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sakoda Teppei¹,Kanamitsu Yoko¹,Mori Yasuo¹²,Sasaki Kensuke¹,Yonemitsu Etsuko³,Nagae Konosuke³,Yoshimoto Goichi¹,Kamezaki Kenjiro²,Kato Koji¹,Takenaka Katsuto²,Miyamoto Toshihiro¹,Furue Masutaka³,Iwasaki Hiromi²,Akashi Koichi¹²

Affiliation:

1. Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan

2. Center for Cellular and Molecular Medicine, Kyushu University Hospital, Japan

3. Department of Dermatology, Kyushu University Graduate School of Medical Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/18/56_8491-16/_pdf

Reference38 articles.

1. 1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092-1097, 2007.

2. 2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790, 2005.

3. 3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369: 2391-2405, 2013.

4. 4. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24: 1128-1138, 2010.

5. 5. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726, 2010.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacillus thuringiensis: a causative agent of pitted keratolysis;Australasian Journal of Dermatology;2021-09-17

2. A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?;Australasian Journal of Dermatology;2021-09-16

3. Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review;Dermatologic Therapy;2020-11-05

4. Necrotizing neutrophilic dermatosis: A diagnostic challenge with a need for multi-disciplinary recognition, a case report;Annals of Medicine and Surgery;2020-09

5. Insights Into the Pathogenesis of Sweet's Syndrome;Frontiers in Immunology;2019-03-12